Literature DB >> 7554014

Compliance with medication among outpatients with uncontrolled hypertension in the Seychelles.

P Hungerbuhler1, P Bovet, C Shamlaye, B Burnand, B Waeber.   

Abstract

Owing to increasing rates of hypertension and cardiovascular-related diseases in developing countries, compliance with antihypertensive medication is major public health importance. Few studies have reported on compliance in developing countries. We determined the compliance of 187 patients with uncontrolled hypertension in the Seychelles (Indian Ocean), by assessing the presence of a biologic marker (riboflavin) in the urine. The urine tested positive in 56% of the cases. Compliance varied from one physician to another (highest 72% versus lowest 33%, P = 0.003), improved with the level of literacy (62% versus 45%, P = 0.024), and depended on the presence absence of diuretics in the medication (respectively, 45% versus 66%, P = 0.005). The ability of patients to report correctly the number of antihypertensive pills to be taken daily was a predictor of compliance (62% of the patients who gave appropriate answers had positive urine for the marker versus 31% for those giving inappropriate answers).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554014      PMCID: PMC2486778     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  21 in total

1.  The effect of prescribed daily dose frequency on patient medication compliance.

Authors:  S A Eisen; D K Miller; R S Woodward; E Spitznagel; T R Przybeck
Journal:  Arch Intern Med       Date:  1990-09

2.  The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly.

Authors:  N Col; J E Fanale; P Kronholm
Journal:  Arch Intern Med       Date:  1990-04

3.  Compliance declines between clinic visits.

Authors:  J A Cramer; R D Scheyer; R H Mattson
Journal:  Arch Intern Med       Date:  1990-07

4.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

5.  Hypertension in developing countries.

Authors:  A Nissinen; S Böthig; H Granroth; A D Lopez
Journal:  World Health Stat Q       Date:  1988

6.  Patient adherence to prescribed therapies.

Authors:  M H Becker
Journal:  Med Care       Date:  1985-05       Impact factor: 2.983

7.  Underutilization of antihypertensive drugs and associated hospitalization.

Authors:  R F Maronde; L S Chan; F J Larsen; L R Strandberg; M F Laventurier; S R Sullivan
Journal:  Med Care       Date:  1989-12       Impact factor: 2.983

8.  High prevalence of cardiovascular risk factors in the Seychelles (Indian Ocean).

Authors:  P Bovet; C Shamlaye; A Kitua; W F Riesen; F Paccaud; R Darioli
Journal:  Arterioscler Thromb       Date:  1991 Nov-Dec

9.  Riboflavin use as a drug marker in Veterans Administration cooperative studies.

Authors:  L M Young; C M Haakenson; K K Lee; J P van Eeckhout
Journal:  Control Clin Trials       Date:  1984-12

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more
  3 in total

Review 1.  A systematic review of adherence to cardiovascular medications in resource-limited settings.

Authors:  Ashna D K Bowry; William H Shrank; Joy L Lee; Margaret Stedman; Niteesh K Choudhry
Journal:  J Gen Intern Med       Date:  2011-08-20       Impact factor: 5.128

2.  Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial.

Authors:  V-M S Ramanujam; Fatima Nayeem; Karl E Anderson; Yong-Fang Kuo; Nai-Wei Chen; Hyunsu Ju; Lee-Jane W Lu
Journal:  Biomarkers       Date:  2016-12-23       Impact factor: 2.658

3.  The Nigerian antihypertensive adherence trial: a community-based randomized trial.

Authors:  Adebowale Adeyemo; Bamidele O Tayo; Amy Luke; Olugbenga Ogedegbe; Ramon Durazo-Arvizu; Richard S Cooper
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.